The synthetic route of 5271-27-2 has been constantly updated, and we look forward to future research findings.
5271-27-2, 1-Methyl-3-phenylpiperazine is a piperazines compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated
5271-27-2, Example 119 and 120lambda/-Cyclopropyl-4-methyl-3-[3-(4-methyl-2-phenyl-1-piperazinyl)-2-oxo-1(2H)- pyrazinylj-benzamide (Example 119) and 3-[5-bromo-3-(4-methyl-2-phenyl-1 – piperazinyl)-2-oxo-1(2H)-pyrazinyl]-lambda/-cyclopropyl-4-methyl-benzamide (Example 120).A mixture of 3-(3,5-dibromo-2-oxo-2/-/-pyrazin-1-yl)-4-methyl-benzoic acid, methyl ester (Example 1 b, 1 15 mg), 1-methyl-3-phenyl-piperazine (77 mg), lambda/,lambda/-diisopropylethylamine (0.1 mL) and tetrahydrofuran (1 mL) was heated within a microwave for 30 minutes at 100¡ãC before being cooled to room temperature. The mixture was transferred to a mixture of palladium on carbon (10percent, 50 mg) and tetrahydrofuran (1 mL) and 1 ,4-cyclohexadiene (1 mL) was added. The mixture was heated under atmosphere of nitrogen within a microwave for 2.5 h at 120¡ãC. An additional portion of palladium on carbon (50 mg) in tetrahydrofuran (1 mL) was added and the mixture was heated for 1 h at 120¡ãC. After cooling, cyclopropylamine (0.3 mL) was added followed by dropwise addition of a solution of /so-propylmagnesium chloride (2M in tetrahydrofuran, 2.5 mL). The mixture was stirred for 10 min. and quenched with sat. aqueous NH4CI and extracted into ethyl acetate. The organic phase was dried (Na2SO4), filtered and concentrated. Purification by preparative HPLC (Gemini column, 0.1 percent ammonia: acetonitrile eluent) afforded lambda/-cyclopropyl-4- methyl-3-(4-methyl-3′-oxo-2-phenyl-3,4,5,6-tetrahydro-2/-/,3’/-/-[1 ,2′]bipyrazinyl-4′-yl)- benzamide (49 mg) and 3-(6′-Bromo-4-methyl-3′-oxo-2-phenyl-3,4,5,6-tetrahydro-2/-/,3’/-/- [1 ,2′]bipyrazinyl-4′-yl)-lambda/-cyclopropyl-4-methyl-benzamide (8 mg).lambda/-Cyclopropyl-4-methyl-3-[3-(4-methyl-2-phenyl-1-piperazinyl)-2-oxo-1(2H)- pyrazinylj-benzamideMS: APCI(+ve) 444 (M+H+).1H NMR .5(DMSO-Cl6, 400MHz) 8.45 (1 H, m), 7.88-7.83 (1 H, m), 7.75 and 7.71 (1 H, 2 x d), 7.52 – 7.42 (3H, m), 7.37 – 7.28 (2H, m), 7.25 – 7.16 (1 H, m), 6.98 (2H, s), 6.17 and 6.07 (1 H, 2 x br s), 3.27 – 3.10 (1 H, m), 2.90 – 2.70 (2H, m), 2.48 – 2.37 (2H, m), 2.20 (3H, m), 2.15 (2H, m), 2.1 1 and 2.04 (3H, 2 x s), 0.69 (2H, m), 0.55 (2H, m).3-[5-Bromo-3-(4-methyl-2-phenyl-1-piperazinyl)-2-oxo-1(2H)-pyrazinyl]-lambda/- cyclopropyl-4-methyl-benzamideMS: APCI(+ve) 522 (M+H+). 1H NMR 5(DMSO-Cl6, 400MHz) 8.42 (1 H, m), 7.85 (1 H, m), 7.77 and 7.74 (1 H, 2 x d), 7.52 – 7.41 (3H, m), 7.37 – 7.28 (2H, m), 7.27 – 7.19 (2H, m), 6.28 and 6.16 (1 H, 2 x br s), 3.29 (3H, s), 3.18 – 3.03 (1 H, m), 2.89 – 2.72 (2H, m), 2.48 – 2.36 (1 H, m), 2.20 (3H, m), 2.15 and 2.07 (3H, 2 x s), 0.69 (2H, m), 0.55 (2H, m).
The synthetic route of 5271-27-2 has been constantly updated, and we look forward to future research findings.
Reference£º
Patent; ASTRAZENECA AB; ASTRAZENECA UK LIMITED; WO2009/1132; (2008); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics